SOFA Score Predicts In-Hospital Mortality for Adults in ICU

Share this content:
SOFA Score Predicts In-Hospital Mortality for Adults in ICU
SOFA Score Predicts In-Hospital Mortality for Adults in ICU

FRIDAY, Jan. 20, 2017 (HealthDay News) -- For patients with an infection-related primary admission to the intensive care unit (ICU), a change of 2 or more points in the Sequential [Sepsis-related] Organ Failure Assessment (SOFA) score offers greater discrimination for in-hospital mortality than systemic inflammatory response syndrome (SIRS) criteria or the quick SOFA (qSOFA) score, according to a study published online Jan. 17 in the Journal of the American Medical Association.

Eamon P. Raith, M.B.B.S., from the Alfred Hospital in Melbourne, Australia, and colleagues conducted a retrospective analysis of 184,875 patients with an infection-related primary admission diagnosis. Data were reviewed for patients from 182 Australian and New Zealand ICUs from 2000 through 2015.

The researchers found that 18.7 percent of the patients died in the hospital. Overall, 90.1 percent had a SOFA score increase of 2 or more points; 86.7 percent manifested two or more SIRS criteria; and 54.4 percent had a qSOFA score of 2 or more points. Compared with SIRS criteria or qSOFA, SOFA demonstrated significantly greater discrimination for in-hospital mortality (area under the receiver operating characteristic curve, 0.753 versus 0.589 and 0.607, respectively; P < 0.001). For the secondary end point of in-hospital mortality or ICU length of stay of three days or more, SOFA outperformed the other scores.

"These findings suggest that SIRS criteria and qSOFA may have limited utility for predicting mortality in an ICU setting," the authors write.

Full Text (subscription or payment may be required)
Editorial (subscription or payment may be required)

Share this content:

is free, fast, and customized just for you!

Already a member?

Sign In Now »


Sign up for myCME e-newsletters


Drug Lookup

Browse drugs by: BrandGenericDisease

Trending Activities

All Professions

More in Home

FDA Approves Bavencio for Merkel Cell Carcinoma

FDA Approves Bavencio for Merkel Cell Carcinoma

Drug targets the PD-1/PD-L1 pathway; first sanctioned treatment in the United States

Heterogeneous Association for Alcohol, CVD Presentation

Heterogeneous Association for Alcohol, CVD Presentation

Non-drinking linked to increased risks of unstable angina, MI, heart failure, ischemic stroke, PAD, AAA

Mobile App Cuts In-Person Visits After Breast Reconstruction

Mobile App Cuts In-Person Visits After Breast Reconstruction

Number of visits down, increase in e-mails to doctors for ambulatory patients undergoing breast recon

is free, fast, and customized just for you!

Already a member?

Sign In Now »